jump to navigation
jump to content
Search in Articles and Documents
generate
PDF
-Version of this page
1:
H
ome
(ALT-H)
2:
H
M
A Joint
(ALT-M)
3:
H
u
man Medicines
(ALT-U)
3.1:
H
e
ads of Agencies
(ALT-E)
3.2:
C
MDh
(ALT-C)
3.3:
M
R
I Product Index
(ALT-R)
3.4:
D
i
rectory
(ALT-I)
4:
V
eterinary Medicines
(ALT-V)
You are here:
Human Medicines
>
CMDh
> Advice from CMDh
3.2.1:
Ab
o
ut CMDh
(ALT-O)
3.2.2:
S
tatistics
(ALT-S)
3.2.3:
P
ress Releases
(ALT-P)
3.2.4:
Procedura
l
Guidance
(ALT-L)
3.2.5:
CMDh-Referrals
3.2.6:
Produc
t
Information
(ALT-T)
3.2.7:
Advice from CMDh
3.2.8:
Templates
3.2.9:
CMD
W
orking Parties / Working Groups
(ALT-W)
3.2.10:
Paediatric Re
g
ulation
(ALT-G)
3.2.11:
Pharmacovigila
n
ce Legislation
(ALT-N)
3.2.12:
Q
uestions & Answers
(ALT-Q)
3.2.13:
Contact Form
3.2.14:
Contact Points
3.2.15:
What's new histor
y
(ALT-Y)
Monitoring of medicines originating from Japan
(November 2012) [
Tracked
]
Abbreviated core Risk Management Plan for bisphosphonates
Guidance on the submission/updating of Risk Management Plans to reflect ‘atypical femoral fractures’
Abbreviated core bisphosphonate RMP for atypical femoral fracture
EU
Worksharing Procedure
Public Assessment Report - Change in qualitative and quantitative composition of rubber stoppers of West Pharmaceutical Services
(July 2008)
